{"id":"W4220992683","doi":"10.1158/1538-7445.sabcs21-p5-13-03","title":"Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Internal medicine; Cohort; Letrozole; Breast cancer; Oncology; Hazard ratio; Cancer; Clinical endpoint; Progression-free survival; Estrogen receptor; Confidence interval; Aromatase; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008924664,0.001112981,0.001487627,0.0006694332,0.001647893,0.0001485437,0.0008869832,0.0001323039,0.003832078],"category_scores_gemma":[0.0001232914,0.0007320744,0.0002129938,0.002917568,0.0009923375,0.000834865,0.0005172021,0.002478658,0.00001532442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003589255,"about_ca_system_score_gemma":0.001171867,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04628,"about_ca_topic_score_gemma":0.005667158,"domain_scores_codex":[0.9898271,0.001901436,0.001170183,0.002054637,0.003254687,0.001791938],"domain_scores_gemma":[0.9947035,0.0008749891,0.0006923074,0.001208088,0.001917618,0.0006034512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2190135,0.02140669,0.3503061,0.00009526564,0.005459756,0.0006872024,0.01868441,0.001024151,0.2839743,0.000004977793,0.001433527,0.09791022],"study_design_scores_gemma":[0.08333506,0.01419805,0.8421112,0.0006719864,0.0002314423,0.00001826387,0.007903687,0.00001918476,0.04983982,0.00002240976,0.0005457181,0.001103196],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9786032,0.003873805,0.00001005571,0.002174668,0.0001612295,0.008491617,0.006384647,0.0001818741,0.0001189256],"genre_scores_gemma":[0.9895932,0.001045918,0.0001377693,0.0004951968,0.0003180804,0.006484421,0.001225153,0.0003254483,0.0003747819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4918051,"threshold_uncertainty_score":0.9998227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05369898673042435,"score_gpt":0.4015396400403317,"score_spread":0.3478406533099073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}